ARS Pharmaceuticals, Inc Strategic Asset Allocation Index
ARS Pharmaceuticals, Inc strategic asset allocation index. ARS Pharmaceuticals, Inc (SPRY) has a Strategic Asset Allocation Index of 0.2% as of June 2023. Strategic assets (PP&E of $594.00K plus long-term investments of $-) total $594.00K, measured against net assets of $248.55 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See ARS Pharmaceuticals, Inc net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of ARS Pharmaceuticals, Inc (2022–2022)
Strategic asset allocation index of ARS Pharmaceuticals, Inc from 2022 to 2022. This chart shows how ARS Pharmaceuticals, Inc's Strategic Asset Allocation Index has evolved across 1 annual periods from 2022 to 2022. As of June 2023, the index stands at 0.2%, representing strategic assets of $594.00K against net assets of $248.55 Million USD. Check tangible equity quality of ARS Pharmaceuticals, Inc to evaluate the tangible quality of the company's equity base.
ARS Pharmaceuticals, Inc Strategic Asset Allocation Index by Year (2022–2022)
ARS Pharmaceuticals, Inc strategic asset allocation index by year from 2022 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for ARS Pharmaceuticals, Inc from 2022 to 2022, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see ARS Pharmaceuticals, Inc (SPRY) total market value.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 0.1% | $329.00K | $329.00K | $- | $272.89 Million | — |